JANX vs RIGL: stock comparison and AI forecast
Janux Therapeutics, Inc. (JANX) and Rigel Pharmaceuticals Inc (RIGL) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
JANX Janux Therapeutics, Inc.
- Market Cap
- $1.07B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
RIGL Rigel Pharmaceuticals Inc
- Market Cap
- $944M
- P/E Ratio
- 3.0x
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- JANX is 1.1 times larger than RIGL by market capitalization ($1.07B against $944M).
- RIGL turns 97.5% of its revenue into net income, against -506.2% for JANX.
- RIGL carries 0.22 times debt per unit of equity, against 0.09 times for JANX.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | JANX | RIGL |
|---|---|---|
| Market Cap | $1.07B | $944M |
| P/E Ratio | – | 2.96x |
| P/B Ratio | 1.15x | 2.22x |
| EPS | $-1.63 | $17.08 |
| Book Value/Share | $15.18 | $22.77 |
| Revenue/Share | $0.33 | $17.67 |
| FCF/Share | $-0.69 | – |
Profitability & Margins
| Metric | JANX | RIGL |
|---|---|---|
| ROE | -11.1% | 75.7% |
| ROA | -10.2% | 61.8% |
| ROIC | -15.2% | 20.5% |
| Gross Margin | – | 92.8% |
| Operating Margin | -708.3% | 26.4% |
| Net Margin | -506.2% | 97.5% |
| EBT Margin | -708.3% | 25.9% |
| Tax Rate | – | -276.2% |
Financial Health
| Metric | JANX | RIGL |
|---|---|---|
| Current Ratio | 16.35x | 1.94x |
| Quick Ratio | – | 1.79x |
| D/E Ratio | 0.09x | 0.22x |
| Financial Leverage | 1.09x | 1.22x |
| Interest Coverage | – | 29.5x |
| Working Capital | $923M | $90M |
Cash Flow
| Metric | JANX | RIGL |
|---|---|---|
| Operating Cash Flow | -$41M | $79M |
| Free Cash Flow | -$42M | – |
| Capital Spending | -$670K | – |
| OCF Growth YoY | – | 20.6% |
| FCF/Sales | -206.9% | – |
| CapEx/Sales | 3.3% | – |
Operational Efficiency
| Metric | JANX | RIGL |
|---|---|---|
| Asset Turnover | 0.02x | 0.63x |
| Receivables Turnover | 136.0x | 5.9x |
| Inventory Turnover | – | 1.7x |
| Fixed Assets Turnover | 6.2x | – |
| Days Sales Outstanding | 3 days | 62 days |
| Days Inventory | – | 220 days |
| Payables Period | – | 61 days |
| Cash Conversion Cycle | – | 221 days |
Income Statement
| Metric | JANX | RIGL |
|---|---|---|
| Total Revenue | $20M | $330M |
| Operating Income | -$144M | $87M |
| Net Income | -$103M | $322M |
| R&D Expense | $124M | $44M |
| SG&A Expense | – | $122M |
| Cost of Goods Sold | – | $24M |
Dividend & Shareholder Information
| Metric | JANX | RIGL |
|---|---|---|
| Shares Outstanding | 61M | 19M |
| Net Income Growth | – | 317.2% |
| EPS Growth | – | 294.5% |
JANX vs RIGL: stock comparison and AI forecast
Which is bigger, JANX or RIGL?
JANX is 1.1 times larger than RIGL by market capitalization ($1.07B against $944M).
Which one does Intratio's AI model rank higher, JANX or RIGL?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.